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Abstract
Background: Rapid treatment of stroke improves outcomes, but accurate early recognition can be challenging.
Between 20 and 40% of patients suspected to have stroke by ambulance and emergency department staff later
receive a non-stroke ‘mimic’ diagnosis after stroke specialist investigation. This early diagnostic uncertainty results in
displacement of mimic patients from more appropriate services, inappropriate demands on stroke specialist
resources and delayed access to specialist therapies for stroke patients. Blood purine concentrations rise rapidly
during hypoxic tissue injury, which is a key mechanism of damage during acute stroke but is not typical in mimic
conditions. A portable point of care fingerprick test has been developed to measure blood purine concentration
which could be used to triage patients experiencing suspected stroke symptoms into those likely to have a non-
stroke mimic condition and those likely to have true stroke. This study is evaluating test performance for
identification of stroke mimic conditions.
Methods: Design: prospective observational cohort study
Setting: regional UK ambulance and acute stroke services
Participants: a convenience series of two populations will be tested: adults with a label of suspected stroke assigned
(and tested) by attending ambulance personnel and adults with a label of suspected stroke assigned at hospital
(who have not been tested by ambulance staff).
Index test: SMARTChip Purine assay
Reference standard tests: expert clinician opinion informed by brain imaging and/or other investigations will assign
the following diagnoses which constitute the suspected stroke population: ischaemic stroke, haemorrhagic stroke,
TIA and stroke mimic conditions.
Sample size: ambulance population (powered for mimic sensitivity) 935 participants; hospital population (powered
for mimic specificity) 377 participants.
Analyses: area under the receiver operating curve (ROC) and optimal sensitivity, specificity, and negative and
positive predictive values for identification of mimic conditions. Optimal threshold for the ambulance population
will maximise sensitivity, minimum 80%, and aim to keep specificity above 70%. Optimal threshold for the hospital
population will maximise specificity, minimum 80%, and aim to keep sensitivity above 70%.
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Discussion: The results from this study will determine how accurately the SMARTChip purine assay test can identify
stroke mimic conditions within the suspected stroke population. If acceptable performance is confirmed,
deployment of the test in ambulances or emergency departments could enable more appropriate direction of
patients to stroke or non-stroke services.
Trial registration: Registered with ISRCTN (identifier: ISRCTN22323981) on 13/02/2019 http://www.isrctn.com/
ISRCTN22323981
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Background
In the UK, stroke is the third leading cause of death and
the single largest cause of adult disability with an overall
economic impact of approximately £9 billion per year
[1]. The cause of stroke is either cerebral ischaemia
(85%) or haemorrhage (15%), and evidence of cost-
effective disability reduction exists for early access to
specialist services (all patients: NNT 20) [2], intravenous
thrombolysis (IVT) for ischaemic stroke <4.5 h since on-
set (10–15% patients: mean NNT 7) [3, 4] and intra-
arterial mechanical thrombectomy (MT) for large vessel
occlusion stroke (LVO) < 6h since onset (5–10% pa-
tients: NNT 3) [5]. To improve access to treatments, na-
tional policy is driving the creation of regional
neuroscience centres (also called comprehensive stroke
centres) with thrombectomy capability or hyperacute
stroke units (HASU; also known as primary stroke cen-
tres) which deliver thrombolysis and provide stroke unit
care [6]. Increasing numbers of patients with suspected
stroke are being redirected past the nearest hospital in
order to access specialist care. Although outcomes are
best when stroke patients are treated rapidly in a HASU
or regional neuroscience centre, the emergency care
pathway for admission is inefficient because accurate ini-
tial diagnosis is often difficult.
Ambulance practitioners, as the first point of contact
in the clinical pathway for the majority of suspected
stroke admissions, use a validated assessment to identify
stroke symptoms and make a decision about where to
take the patient [7]. Clinical guidelines specify that any
suspected stroke should be conveyed directly to the
nearest specialist stroke care centre [7]. The most widely
used assessment is the Face Arm Speech Test (FAST),
which records facial weakness, arm weakness and/or
speech disturbance [8]. Although FAST has good sensi-
tivity, poorer specificity results in 30–50% of ‘FAST posi-
tive’ patients later receiving a non-stroke ‘mimic’
diagnosis (i.e. false positives) [8, 9]. At hospital emer-
gency departments, emergency medical staff can quickly
identify more non-stroke mimic conditions during clin-
ical assessment than ambulance practitioners, but the
mimic rate is still 20–30% [10] resulting in frequent re-
ferral of mimics to stroke units rather than to
appropriate alternative services according to the under-
lying condition.
This early diagnostic uncertainty can therefore result
in displacement of mimic patients from more appropri-
ate local hospitals or medical specialties within a hos-
pital, inappropriate demands on finite stroke specialist
resources and delayed access to specialist care and time-
critical reperfusion therapies for true stroke patients. For
example, national audit in England consistently shows
that 44% of confirmed stroke patients are not admitted
to a HASU within 4 h of hospital arrival [11], and as it
has been observed that 15–20% HASU beds are occu-
pied by patients with mimic conditions for a typical stay
of 2.5 days [12], one explanation for the inability to
achieve stroke service standards is the impact of ‘false
positive’ stroke admissions (i.e. mimics) upon finite spe-
cialist resources.
Blood biomarkers have potential advantages in emer-
gency assessment but have not previously proven useful
during the critical early stages of stroke as release occurs
hours after onset, and complex assays are required [13–
15]. However, evidence is now accumulating that detec-
tion of whole blood purine concentration (WBPC) may
be able to assist with stroke versus mimic identification
[16–19]. Purines are short half-life natural by-products
from energy-producing metabolic pathways which accu-
mulate rapidly during hypoxic tissue injury [16]. Hypoxia
is a main pathophysiological mechanism when stroke is
caused by ischaemia (due to arterial occlusion) or haem-
orrhage (due to associated pressure effects and vasocon-
striction), but for most common mimic conditions,
significant tissue hypoxia is not involved (e.g. migraine).
Whilst purines are not a tissue-specific biomarker and
are elevated in other hypoxic states, cerebral tissue is a
particularly rich source because of its high metabolic ac-
tivity and oxygen sensitivity. In the clinical context of
suspected stroke, a significant WBPC difference is ex-
pected between common mimic conditions (low WBPC
values) and true stroke (higher WBPC values).
A portable point of care novel biosensor assay
‘SMARTChip Purine’ has been developed to measure
WBPC from a fingerprick drop of capillary blood
[19]. The assay consists of enzymatic biosensors
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printed within a strip of carbon substrate and a be-
spoke reader device. A coupled cascade of three en-
zymes (adenosine deaminase, purine nucleoside
phosphorylase and xanthine oxidase) quickly detects
the combined concentrations of purine: adenosine, in-
osine and hypoxanthine [17]. Figure 1 shows the
SMARTChip technology.
The SMARTChip assay could be used to triage pa-
tients with suspected stroke symptoms into those
people likely to have a non-stroke mimic condition
and those likely to have true stroke. The assay may
have maximum impact if deployed pre-hospital but
may also be of use on arrival at hospital for patients
who do not present to the ambulance service, or if
the technology is not available in the ambulance or
was not deployed by ambulance practitioners because
stroke was not suspected. In both settings, the assay
result would be useful for determining whether pa-
tients with suspected stroke symptoms continue along
the stroke emergency assessment pathway or whether
they should be directed to other more appropriate
emergency services for further assessment and treat-
ment (i.e. the test result indicates that a patient is
likely to have a non-stroke mimic condition).
The SMARTChip assay may also have an alternative
purpose in the context of suspected stroke. Due to
the greater volume of brain tissue involved during
LVO stroke, it is hypothesised that WBPC readings
will be elevated higher and for a longer time period
when compared to both mimic conditions and those
stroke patients without LVO. Sequential SMARTChip
assay readings may therefore be able to assist in iden-
tification of patients with LVO stroke. As time-critical
mechanical thrombectomy treatment is only available
in a small number of regional neuroscience centres
(comprehensive stroke centres), patients with LVO
suitable for thrombectomy typically require secondary
transfer from a HASU. Rapid identification of mech-
anical thrombectomy-eligible patients could facilitate
transfer and expedite access to treatment.
The main aim of this study is to evaluate the diagnos-
tic accuracy of the SMARTChip assay for identification
of stroke mimic conditions amongst the suspected
stroke population when used in either the pre-hospital
or hospital environment. An exploratory substudy will
be conducted to assess whether serial WBPC values
could be useful for the identification of LVO stroke.
Methods
Study objectives
1. To determine the diagnostic accuracy of SMARTChip
assay WBPC readings for identification of stroke
mimic conditions when a reading is obtained in
the pre-hospital setting, i.e. the test is conducted
on patients suspected to have stroke by ambulance
staff
2. To determine the diagnostic accuracy of SMARTChip
assay WBPC readings for identification of stroke
mimic conditions when a reading is obtained in
hospital, i.e. the test is conducted on patients
suspected to have stroke by hospital staff and
when an ambulance test has not been undertaken
3. To develop pre-hospital and hospital statistical
models which combine routinely available clinical
data with SMARTChip assay WBPC readings to
predict a stroke mimic diagnosis
4. To prospectively determine the diagnostic accuracy
of the statistical models from objective 3
5. To report the failure rate of the SMARTChip assay
when used in the pre-hospital and hospital settings
Substudy
1. To explore the diagnostic accuracy of two
sequential SMARTChip assay WBPC readings for
identification of LVO stroke using a reading
obtained in the pre-hospital setting and a second
reading obtained in the hospital setting
2. To develop and retrospectively explore the
diagnostic accuracy of a statistical model which
combines routinely available clinical data with pre-
hospital- and hospital-obtained SMARTChip
WBPC readings to predict the presence of LVO
Study design
Two prospective blinded observational cohort studies
will be conducted, one involving a convenience series of
Fig. 1 SMARTChip technology
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suspected stroke patients tested by hospital services and
one involving a convenience series of suspected stroke
patients tested by ambulance services. There will be 5
phases:
Phase 1: pilot cohort study in hospital to review key
technical performance parameters of the SMARTChip
assay
Phase 2: main hospital cohort study part 1. Once
agreement is reached that technical performance is
satisfactory, data will be collected to determine the
diagnostic accuracy of WBPC assay readings for
identification of mimic conditions (objective 2) and to
build the statistical model (objective 3).
Phase 3: main hospital cohort study part 2. Data will be
prospectively collected to confirm the diagnostic
accuracy of (i.e. validate) the hospital statistical model
(objective 4).
Phase 4: ambulance cohort study part 1. Data will be
collected to determine the diagnostic accuracy of
WBPC assay readings for identification of mimic
conditions (objective 1) and to build the statistical
model (objective 3).
Phase 5: ambulance cohort study part 2. Data will be
prospectively collected to confirm the diagnostic
accuracy of (i.e. validate) the ambulance statistical
model (objective 4).
Phases 4 and 5 may overlap with phases 2 and 3 de-
pending on logistical factors, e.g. time taken to com-
mence ambulance service involvement or availability of
sufficient testing equipment.
Data collection to report the failure rate of the
SMARTChip assay will run across phases 2–5. Data col-
lection for the substudy is relevant to phases 4 and 5 only.
Study setting
The hospital cohort study will take place within well-
established acute stroke services with clinical access to
CT or MR angiography (CTA/MRA) and at least day-
time presence of a specialist stroke team. The ambulance
cohort study will be hosted by regional ambulance ser-
vices feeding into these stroke services. The research en-
vironment will reflect the local care pathway for patients
with acute stroke symptoms including the scene of the
incident, ambulance, emergency department and stroke
service.
Study participants
Both pre-hospital and hospital patients will fulfil the fol-
lowing criteria to undergo an assay reading:
Inclusion criteria:
 Aged 18 years and over
 At least responsive to strong stimuli during
assessment of conscious level (alert, voice or pain on
the Alert, Voice, Pain, Unresponsive (AVPU) scale)
 Face Arm Speech Test (FAST) positive or any
observed new focal neurological symptoms
indicating suspected acute stroke
 Persistence of the new stroke-like symptoms during
the initial clinical assessment
 Believed to be within 6 h of onset of the new stroke-
like symptoms at the time of the first clinical
assessment
 SMARTChip assay WBPC reading can be
undertaken before receipt of any reperfusion
therapies
 Pre-hospital patients will only be included if they are
to be transported to a study hospital
 Patients will only be included in the hospital cohort
if they have not had a pre-hospital reading
attempted
Exclusion criteria:
 Hypoglycaemia (capillary glucose <3.5mmol/l)
 External signs of significant acute trauma which are
likely to need additional treatment (large
haematomas, open wounds, limb deformity)
 Chemotherapy or radiotherapy treatment for cancer
within the last 7 days
In order to provide a population to fulfil the objectives
of the substudy, trained hospital staff (when available)
will attempt an assay reading on the following subgroup
of patients:
 Had an assay reading attempted by ambulance
personnel
 The symptoms resulting in admission are believed to
have commenced within 6 h of the time that the
hospital assay can be performed
 The hospital assay can be performed before IVT or
MT if this treatment is indicated
Participant identification and consent
Ambulance and hospital personnel will determine suit-
ability for the SMARTChip WBPC assay from their rou-
tinely conducted clinical assessments. Because the
assessment of suspected stroke patients needs to be per-
formed rapidly in order to minimise delays in accessing
time-dependent treatments, patients will be approached
about study enrolment after the initial emergency
assessment and treatment processes, including the
SMARTChip assay(s), have been completed. A formal
research consent process performed in the ambulance or
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immediately on hospital arrival would cause unaccept-
able delays.
All patients who had either an ambulance and/or hos-
pital WBPC reading attempted will be approached for
study enrolment. An assay reading attempt will be de-
fined as a fingerprick sample procedure being under-
taken. As described below (see ‘SMARTChip Purine
assay (index test)’), there may be occasions when the
assay technology fails to calibrate and progression to fin-
gerprick sampling is not possible. In such cases, patients
will not have undergone any research procedures, and
approach for consent will not occur. However, as failed
calibration provides important test usability information,
non-identifiable data about the test attempt will be re-
corded and reported.
Approach of patients for study enrolment will be by
appropriately research-trained clinical staff or NHS re-
search support staff. Ideally, approach of patients will
take place during their inpatient stay and as soon as pos-
sible after the emergency assessments and treatments
have taken place such that a timely discussion about the
study can be held. However, for a small number of pa-
tients, this may not be possible because of early dis-
charge, transfer or death, and in these situations,
alterative consent methods will be used as described
below.
Consent
The consent process will seek permission for retention
and analysis of WBPC assay data and collection of se-
lected routinely recorded healthcare data which are es-
sential to complete the study objectives. There are no
additional study-specific assessments.
Consent for patients who can be approached about study
participation during their inpatient stay
Consent for patients with mental capacity
For patients with capacity to consent to research, a
trained member of the clinical team or NHS research
support staff will approach the patient to discuss the
study and provide a patient information sheet. After
allowing sufficient time for potential participants to de-
cide whether to take part in the study and an opportun-
ity to ask questions, consent will be obtained in writing.
When a patient has mental capacity but is unable to sign
the consent form (e.g. because of weakness of the dom-
inant hand following stroke), consent will be confirmed
orally in the presence of a witness (an individual not
otherwise involved in the trial), and the witness will sign
and date the consent form on behalf of the participant.
If a potential participant is due to be discharged and
wishes to have longer to consider the information before
making a decision, staff will provide a postal consent
form and prepaid reply envelope which can be returned
if a decision to take part is made.
Consent for patients with mild communication difficulties
For patients with mild communication difficulties due to
the effects of a stroke or mimic condition, a set of ‘easy
access’ study documentation will be used. After allowing
sufficient time for the information to be considered and
an opportunity to ask questions, consent will be ob-
tained in writing using the ‘easy access’ consent form.
If a potential participant is due to be discharged and
wishes to have longer to consider the information before
making a decision, an ‘easy access’ postal consent form
and prepaid envelope are available for use. Staff will con-
sider the appropriateness of such forms prior to issue in-
cluding the availability of a relative/friend to assist with
completion. If a postal form is judged to be inappropri-
ate, the potential participant will be offered the oppor-
tunity to return for further discussion and consent at a
later date.
Consent for patients who lack mental capacity
It is anticipated that approximately one third of study
eligible patients will be unable to engage with an in-
formed consent process due to the effects of stroke and
mimic conditions upon communication and cognition.
As exclusion of this group would drastically reduce the
clinical relevance of the study, if a patient is unable to
provide consent, a personal or nominated (professional)
consultee will be approached as further described below.
It is anticipated that the majority of patients will be
approached about participation within 24 h of admission
which is typical for clinical trials of emergency stroke
care. If at this time, a potential participant is believed to
be lacking in capacity to consent to research, the staff
making this first approach (appropriately trained clinical
staff or NHS research support staff) will confer with the
attending clinical team to determine the likelihood that
this patient will improve and recover capacity by 48 h
after admission. If it is considered that the patient is un-
likely to recover capacity in this time, staff will proceed
to attempt to identify an appropriate personal consultee
(usually the next of kin) to approach, discuss the study
and provide a consultee information sheet. If a personal
consultee is identified, after allowing sufficient time for
him/her to consider the patient’s wishes and feelings and
an opportunity to ask questions, the consultee will be
asked to complete a consultee declaration form if they
believe that the patient would have no objection to tak-
ing part in the study. If the potential participant is due
to be discharged and the personal consultee wishes to
have longer to consider participation, staff will provide a
postal personal consultee declaration form and prepaid
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reply envelope which can be returned if a decision to
take part is made.
In the event of being unable to locate an appropri-
ate personal consultee by 48 h after admission, an in-
dependent clinician (nominated consultee) will be
approached to confirm that the patient lacks capacity
for consent and that study participation would not
introduce a risk of harm or be against the patient’s
wishes from what is known about their character and
beliefs. The independent clinician will sign a nomi-
nated consultee declaration form concerning study
participation.
If when a patient is first approached they are be-
lieved to be lacking in capacity to consent to research
and after conferring with the clinical team it is con-
sidered that the patient is improving and therefore
may recover capacity to discuss the study, approach
about consent will be delayed for 24 h. A further re-
view of capacity will then be undertaken. If at this
time the patient has recovered capacity, staff will
proceed to seek consent directly from the patient.
However, if the patient remains unwell and lacking in
capacity, staff will proceed as described above to ap-
proach a personal consultee or independent clinician.
Consent and early mortality
The early mortality rate following acute stroke is ap-
proximately 10%. Some mimic conditions are also asso-
ciated with a high mortality, e.g. severe infection.
Exclusion of patients that die soon after admission
would reduce the study’s relevance for the typical sus-
pected stroke population.
If a patient who underwent a SMARTChip assay at-
tempt dies before consent can be obtained using one of
the approaches described above, the local principal in-
vestigator will sign an Early Mortality Declaration Form
to confirm that the patient has died, and take responsi-
bility for the use of routinely collected healthcare data
for this research project.
Consent for patients who are only identified after
discharge or transfer from the admitting hospital
Patients who are only identified as having undergone a
SMARTChip assay after discharge or transfer from the
admitting hospital will be invited to take part by post.
An invitation letter, participant information sheet, con-
sent form and prepaid return envelope will be mailed.
The letter will include a telephone number of the admit-
ting hospital research team to answer any queries or dis-
cuss the study in more detail. Patients willing to take
part in the study will be asked to return a completed
consent form.
As it will not be possible to assess mental capacity
or communication issues prior to a postal invitation,
the invitation letter includes a specific section for a
person reading the letter who is not the intended re-
cipient but reading it on their behalf. The reader is
informed that the recipient can take part in the re-
search and is asked to contact the hospital team for
discussion and further information. If contacted, the
hospital team will discuss the study and offer either a
face-to-face appointment to obtain consent or to post
the appropriate form (i.e. the easy access postal con-
sent form or the personal consultee postal declaration
form).
For invited patients who have not returned a consent
form within 2 weeks, or where there has been no other
contact about an invited patient, the local hospital re-
search team will follow up with one telephone call.
Changes in capacity to consent to research during
participation in the study As there are no additional
study-specific assessments and only collection of rou-
tinely available healthcare data in this project after the
SMARTChip assay, changes in capacity status will not
be reviewed.
Consent not obtained If a patient or a consultee de-
clines the invitation to be included in the study or a pos-
tal consent form is not returned, or if consent by one of
the approaches above is not obtained for any other rea-
son, collected data will be retained at the local site to
document that a SMARTChip assay measurement(s)
was undertaken but no further study data will be col-
lected. The researchers will be informed that a test was
conducted but consent was not obtained and no further
data will be provided.
Figure 2 summarises the decision process for obtaining
study consent.
SMARTChip purine assay (index test)
The diagnostic technology under evaluation comprises
four tiny electrochemical biosensors printed in carbon
on strip of ceramic substrate (50 × 10 × 1 mm) (called
‘SMARTChip Purine’) and a bespoke portable reader de-
vice. A coupled cascade of three enzymes (adenosine de-
aminase, purine nucleoside phosphorylase and xanthine
oxidase) detects the combined concentrations of the pu-
rines: adenosine, inosine and hypoxanthine. To take a
measurement, the user inserts the SMARTChip into the
reader, performs a calibration and buffer step and then
adds a drop of blood from a fingerprick sample. The
procedure takes 6 to 8 min and can be completed in par-
allel with other aspects of the standard emergency care
pathway for suspected stroke. As the study is blinded,
the assay reading is not displayed anywhere and is only
accessible to the researchers in the data downloaded
from the reader (see below).
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There may be occasions when an assay step fails, i.e.
calibration, buffer or the WBPC measurement. If any step
fails, to repeat the assay, a new SMARTChip is required.
In the pre-hospital setting, only one attempt using one
SMARTChip will be permitted to avoid the possibility of
causing delays to patient transport to hospital, e.g. if
calibration fails, the procedure will be abandoned at this
point. For the hospital setting, if the calibration or buffer
Fig. 2 Decision process for study consent
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step fails, up to two further attempts will be permitted as
this is unlikely to delay care (i.e. use up to three
SMARTChips). However, only one fingerprick will be per-
mitted and therefore only one attempt at the blood
measurement step.
Following any assay attempt, the bespoke reader device
will be connected to a designated password-protected
study laptop, and reading data will be downloaded. Data
will subsequently be provided to the research team
(consented patients only) either manually via encrypted
USB drives or over the internet. No patient identifiable
data is added to the reader or downloaded into the study
laptop.
Verification of WBPC assay results
Each WBPC assay result combines readings from the
four individual SMARTChip electrodes. Due to the con-
ditions under which SMARTChip will be deployed dur-
ing the study, including handling by users who are less
familiar with the technology, it is possible that the elec-
trical contacts, electrodes or enzyme coating are dam-
aged. Even though the SMARTChip passes the
calibration stage, one or more of the four small elec-
trodes may produce readings which are not physiologic-
ally or electrochemically plausible. The raw data from an
assay passes through additional reader software to com-
pute the WBPC result. This software will label the read-
ings as electrochemically plausible ('verified') or not. All
data will be used in the study analyses, but 'verified' and
‘unverified’ results will be handled separately (see ‘Main
ambulance and hospital study analyses’ section).
In addition, staff from Sarissa Biomedical (technology
manufacturer) will subject the biosensor current readings
to an automated check using validated software. This is to
review that the data quality controls within the reader are
functioning appropriately. In the event that the automated
check suggests a malfunction (for example a verified read-
ing should be unverified or vice versa), a report will be
prepared and presented to the study steering committee
who will make a decision about whether there is justifica-
tion to alter the reading accordingly. The automated
check will occur without access to any clinical data, and
any alterations will be recorded.
Unverified readings may be related to malfunctioning
SMARTChips or user error, and this will be monitored
by staff from Sarissa Biomedical. If there is a clustering
of unverified readings associated with a particular pro-
duction run of SMARTChips; then, others from that
batch will be replaced and local storage conditions
reviewed. If the assay data generated by any user shows
a pattern suggestive of incorrect SMARTChip use, the
user will be invited to attend refresher training.
Reference standards (comparator)
Main study
For the main study, reference standards are required to as-
sign the following clinical diagnoses which constitute the
suspected stroke population: ischaemic stroke, haemor-
rhagic stroke, TIA and stroke mimic conditions. Whilst
brain imaging tests are available which objectively confirm
haemorrhagic stroke, no single diagnostic test exists for is-
chaemic stroke, TIA and many stroke mimic conditions.
Because of this, diagnoses will be assigned by a local hos-
pital expert clinician and confirmed via independent adju-
dication as described in detail below.
Hospital expert clinician opinion informed by brain
imaging ± other investigations as clinically appropriate
will be used to select a diagnosis from a predefined diag-
nosis framework (Table 1). This framework is being used
because primary medical diagnoses recorded in medical
records can vary according to the taxonomy used and
the terminology preferred by individual clinicians, e.g. chest
infection is synonymous with pneumonia, bronchopneu-
monia and lower respiratory tract infection. Clinicians will
be asked to select a ‘definite’ or ‘probable’ primary clinical
diagnosis according to the framework. As diagnoses are
sometimes uncertain for a time after admission to hospital,
clinicians will be asked to provide the diagnosis assigned at
7 days after hospital admission or at discharge/death if
sooner. The framework includes an option for ‘unclear’ if
the clinician cannot assign a diagnosis. In order to facilitate
consistent completion of the framework, guidance has been
developed to assist clinicians in allocation of a definite,
probable or unclear diagnosis (Table 2).
Following assignment of a diagnosis, clinical and im-
aging data collected for the study will be reviewed by an
independent clinician at the study coordinating centre to
determine if the diagnosis assigned and clinical/imaging
information concur. If data do concur, the assigned diag-
nosis will be confirmed as appropriate. If the data do not
concur, the case will be discussed by a Diagnostic Adjudi-
cation Committee which will comprise a stroke specialist
from the study coordinating centre team, the local hos-
pital clinician responsible for assigning the diagnosis and
another local clinician who was not involved in making
the diagnosis. All are blinded to the SMARTChip assay
outcome. The committee will meet by teleconference and
review anonymised routine clinical information available
up to day 7 or discharge if sooner, to agree a diagnosis.
In addition, irrespective of whether the local diagnosis
assigned and clinical/imaging data concur or not, where
‘unclear’ or ‘probable’ stroke mimic diagnoses (categories
B–J in the framework) are selected, Diagnostic Adjudica-
tion Committee review will take place. This is to check
that there is reasonable evidence that these categories
are appropriate as typically there will be greater reliance
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Table 1 Primary diagnosis framework
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Table 1 Primary diagnosis framework (Continued)
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upon clinical judgement than objective information from
any routine investigations.
For ‘unclear’ cases, if the committee cannot reach con-
sensus (e.g. because of missing clinical information or lack
of adjudicator consensus), the final diagnosis will still be
listed as ‘unclear’, and these patients will not be included in
the diagnostic accuracy analyses as it has not been possible
to determine any diagnosis. Data for these partici-
pants will still be reported. All other diagnoses will
be used in the analyses as described in the ‘Statistical
analyses’ section.
Substudy
For the substudy, a reference standard is required for is-
chaemic stroke with LVO. Angiography of the cerebral cir-
culation via CT or MR imaging conducted as part of
standard clinical care will be used. Angiography is not rou-
tinely performed for all suspected stroke patients as
Table 1 Primary diagnosis framework (Continued)
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clinical or non-contrast radiological examination can de-
cree it unneeded. It is usually performed for patients with
National Institute for Health Stroke Scale (NIHSS) [20]
score of >5 presenting within 6 h of symptoms onset,
where plain CT has not shown a haemorrhage or another
radiological diagnosis for the acute symptoms, e.g. tumour.
For patients undergoing CT or MR angiography
(CTA or MRA), LVO will be defined as present if
angiography demonstrates reduced filling in any large
branch of the anterior cerebral circulation as assessed
using the Ten Point Clot Burden Score [21]. A score
<10 will indicate the presence of LVO. All CTAs will
be reported by a consultant neuroradiologist blinded
to patient and study information. Local clinical rou-
tine imaging reports will also be obtained if available,
but these will not alter the data to be used for the
main study analyses. The frequency and nature of any
discrepancies between the reports will however be
reported on study completion.
For participants who do not undergo angiography be-
cause they do not meet the clinical criteria (e.g. mimic
conditions, haemorrhagic stroke, mild ischaemic stroke
with NIHSS < 6 and TIA) and the probability of LVO is
remote, it will be assumed that they do not have
LVO. However, there may also be participants with
ischaemic stroke of sufficient severity to be potentially
caused by LVO (i.e. NIHSS >5), but who do not
undergo angiography. This is usually because of an
early clinical judgement that they would not be of-
fered MT (e.g. due a low Alberta Stroke Program
Early CT Score [22] or significant comorbidities) or
because MT is not available. For these participants, it
will not be possible to make a confident assumption
about LVO status, and therefore, their data will not
be included in diagnostic accuracy analyses concern-
ing LVO. Available data for these participants will
still be reported.
Study data collection
For participants who give consent for enrolment in this
study, SMARTChip WBPC assay data, clinical diagnosis
data, imaging data and routine healthcare data to con-
firm study eligibility and conduct study analyses will be
collected. WBPC assay data will be recorded by the
SMARTChip reader and subsequently harvested to be
linked with clinical data. The SMARTChip assay
process, imaging data, clinical diagnosis data and other
routine healthcare data will be recorded onto study-
specific case record forms (CRFs) by ambulance
personnel, NHS research support staff or other hospital
clinical staff trained to deliver this research project.
Data from CRFs will be entered locally onto a secure
online database. Patients will be identified by a unique
study number only (for ambulance-tested patients, the
ambulance used SMARTChip ID number; for hospital
only tested patients where calibration/buffer of more
than one SMARTChip is permitted, the ID number of
the SMARTChip which had the blood sample applied
will be used). Where consent is not obtained, non-
identifiable data about the assay attempt only will be
added to the study database to allow the total number of
assay attempts to be reported.
Table 2 Guidance for completion of the primary diagnosis framework
Framework
diagnosis




Symptoms typical for a vascular territory.
Time course typical of stroke or TIA.
Vascular risk factors are present.
Imaging supports the clinical diagnosis





Symptoms mostly typical of a vascular territory.
Time course suggestive of stroke or TIA.
No vascular risk factors or a less common cause of stroke
or TIA.
Imaging supports the clinical diagnosis
with no suggestion of an alternative
aetiology.





Positive clinical evidence from history/examination and/
or previous medical history consistent with a mimic
condition
Evidence consistent with a mimic
diagnosis on CT/MRI imaging or other
investigations.
No new secondary prevention.
Probable
mimic
Symptoms more suggestive of a mimic than a vascular
territory.
Vascular risk factors may be present.
No relevant PMH of a mimic condition
No CT or MRI evidence of new stroke but
no alternative imaging diagnosis.
No mimic diagnosis suggested by other
investigations.
No new secondary prevention.
Unclear Symptoms not typical of a vascular territory and/or time
course not typical of stroke or TIA.
No reason for stroke or TIA to occur.
No positive clinical evidence from history/examination or
previous medical history consistent with a mimic
condition
No CT or MRI evidence of new stroke but
no alternative imaging diagnosis.
No mimic diagnosis suggested by other
investigations.
Simple or no new secondary
prevention considered
appropriate.
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Data related to pre-admission, collected if an ambulance
reading attempt was undertaken, recorded by ambulance
staff
Data about ambulance SMARTChip assay SMARTChip
ID number (will be provided on sticky labels to add to
study forms to avoid transcription errors), date and time
of completion of the SMARTChip assay, any complica-
tions from fingerprick sampling (no/yes: free text), any
reason for the SMARTChip assay process to be aborted
before completion (no/yes: free text)
Data for confirmation of inclusion and exclusion
criteria Age, symptom onset or last known to be well
date and time (ambulance personnel judgement),
symptoms which suggest stroke (face weakness, arm
weakness, speech disturbance, leg weakness, visual loss,
eye deviation, double vision, other), first recorded con-
scious level (AVPU scale), first recorded capillary
blood glucose reading, any external signs of acute
trauma (yes/no), received chemotherapy or radiother-
apy for cancer within the last 7 days (yes/no), hospital
conveying to
Other data related to pre-admission Professional who
suspected stroke (technician, paramedic, other ambu-
lance role), first systolic blood pressure reading, first
heart rate reading, first peripheral oxygen saturation
reading, aural temperature reading, possible blackout
today (yes/no/unknown), possible seizure today (yes/no/
unknown), current headache (yes/no/unable to respond),
previous medical history of epilepsy (yes/no/unknown),
previous medical history of migraine (yes/no/unknown),
date and times of 999 call; ambulance on scene and hos-
pital arrival.
Data related to a hospital reading attempt and recorded by
hospital staff
Hospital SMARTChip ID number(s) (will be provided
on sticky labels to add to study forms to avoid tran-
scription errors), date and time of completion of the
hospital SMARTChip assay, complications from finger-
prick sampling for hospital SMARTChip assay (no/yes:
free text), any reason for the hospital SMARTChip
assay process to be aborted before completion (no/yes:
free text)
Data related to day 1 of admission, collected if either an
ambulance and/or a hospital reading attempt was
undertaken and consent is obtained, recorded by hospital
staff
Demographic information (age, gender), date and time
of hospital admission, first recorded conscious level on
admission (AVPU scale), first blood pressure reading on
admission, first heart rate reading on admission, first
temperature reading on admission, first peripheral oxy-
gen saturation on admission, first blood glucose reading
on admission (capillary or serum glucose), any external
signs of acute trauma noted on first clinical examination
(yes/no), symptom onset or last known to be well date
and time (hospital judgement), previous vascular history
(stroke, TIA, heart failure, atrial fibrillation, diabetes,
hypertension), previous neurological history (migraine,
seizures, any diagnosis of dementia), recent significant
trauma history within the preceding 7 days (surgery,
fractures, wounds), recent inflammation history within
the preceding 7 days (infections requiring new antibiotic
treatment, intravenous chemotherapy treatment or
radiotherapy received, acute exacerbation of a musculo-
skeletal condition, e.g. gout), current medication history
(dipyridamole, anticoagulants, allopurinol), usual level of
mobility (independent, independent with walking aid,
physical assistance, cannot walk), standard laboratory
bloods on admission (renal function: creatinine, urea, so-
dium, potassium; glucose; C-reactive protein; full blood
count: haemoglobin, leucocytes, platelets), hospital ad-
mission (yes/no, discharged/no, transferred directly to
another hospital/no, died in ED), date and time left ED,
first ward if admitted locally (stroke unit/medical admis-
sions ward/other medical ward/trauma ward/surgical
ward/other), destination ward if transferred directly to
another hospital (neurosurgical/stroke unit/trauma/
other), stroke symptom severity on admission (National
Institute of Health Stroke Score [20] -this is routinely
documented for most suspected stroke patients, but if
this is found to be missing from routine records, it will
be completed by the NHS research team from direct as-
sessment of the patient or using the clinical examination
documented in routine records), most likely clinical stroke
subtype according to new symptoms (Oxford Community
Stroke Project classification [23]), intravenous thromboly-
sis treatment administered (yes/no), date and time of
bolus administration (if thrombolysis received), mechan-
ical thrombectomy treatment administered (yes/no), date
and time of arterial puncture (if thrombectomy received),
if thrombolysis or thrombectomy were received, NIHSS
recorded at 24–48 h after treatment
If a hospital only assay reading attempt was
undertaken Symptoms which suggested stroke (face
weakness, arm weakness, speech disturbance, leg weak-
ness, visual loss, eye deviation, double vision, other), pro-
fessional who suspected stroke at hospital (ED nurse, ED
junior doctor, ED senior doctor, stroke nurse, stroke
junior doctor, stroke senior doctor)
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If an ambulance assay reading was attempted but a
hospital assay (for the sub-study) was not Reason why
hospital WBPC assay was not attempted (patient >6h
since symptom onset/admitted out of hours/trained assay
user not available/reader malfunction/no SMARTChip
available/other)
Data related to day 7 of admission (or death/discharge if
this is sooner than day 7) collected if either an ambulance
and/or hospital reading attempt was undertaken and
consent is obtained, recorded by hospital staff
Deceased, inpatient or discharged alive at day 7, if de-
ceased, cause of death according to death certificate, if
discharged, discharge date, confirmation that symptom
onset date/time recorded on day 1 is still correct at day
7 or death/discharge (no change/change. If changed:
new date/time), length of stay on the stroke unit (0–7
days), COVID-19 status (if available), primary clinical
diagnosis for this attendance in place at day 7 as docu-
mented in the medical records (free text), primary
clinical diagnosis in place at day 7 according to a pre-
defined framework, description of the clinical rationale
on which the primary clinical diagnosis (according to
the pre-defined framework) was selected (free text to de-
scribe clinical features including vascular risk factors
and investigations), for all participants, an anonymised
copy of the discharge letter will also be requested. This
will be used during independent adjudication of refer-
ence standard diagnoses.
Imaging data collected if either an ambulance and/or
hospital reading attempt was undertaken and consent is
obtained, recorded by hospital staff
Brain imaging performed (yes/no), brain imaging date(s),
time(s) and modality (CT/MR/CTA/MRA/CTP) per-
formed during the first 7 days of admission (or death/
discharge if sooner), brain imaging result(s) free text
(formal reports/entries in the medical records if formal
reports are unavailable), CT or MRI angiography
performed on day 1 (yes/no), CT perfusion imaging
performed on day 1 (yes/no), if perfusion imaging
performed (according to the local radiological software
output): core volume (CV: ml), penumbra volume (PV:
ml), cerebral blood volume (CBV: ml), time to peak
(TTP: seconds), mean transit time (MTT: seconds),
cerebral blood flow (CBF: ml/s)
For participants whose data will be included in the sub
study (i.e. those where a hospital SMARTChip assay
followed an ambulance assay), anonymised CT, CTA,
MR and MRA images performed in the acute phase (i.e.
< 12 h since symptom onset) will also undergo separate
blinded neuroradiologist review using a checklist to rec-
ord: changes of cerebral ischaemia, Alberta Stroke Pro-
gram Early CT Score [22], other pathological findings
(e.g. subdural haematomas, tumours, subarachnoid
blood), Ten Point Clot Burden Score [21], and Extended
Thrombolysis in Cerebral Infarction scale [24].
Blinding
Patients, clinicians and research support staff will be
blinded to WBPC results. Clinicians responsible for adjudi-
cation and neuroradiologists responsible for providing the
independent imaging reports will also be blinded to WBPC
results. Checks on raw WBPC data conducted by Sarissa
Biomedical staff will be without access to any clinical data.
Staff training and awareness
Study-specific training will be provided for ambulance
personnel, stroke teams and research support staff in ses-
sions which will explain the study objectives and demon-
strate use of the SMARTChip and Reader and completion
of the study documentation and database as appropriate.
Study withdrawal
No specific withdrawal criteria have been pre-set. Partic-
ipants may withdraw from the study at any time for any
reason. Data collected prior to withdrawal will be used
in the study analysis unless the patient or their represen-
tative requests that this should not be the case. Should a
decision to withdraw from the study be made, a reason
for withdrawal will be sought, but participants can
choose to withdraw without providing an explanation.
Safety evaluation
This is a clinician-blinded observational study of a
new diagnostic technology which will not change pa-
tient treatment. The fingerprick sampling procedure
for the WBPC assay is already performed by ambu-
lance and hospital staff during routine measurement
of capillary blood glucose concentrations on all sus-
pected stroke patients. The procedure for capillary
sampling for the WBPC assay is identical to this rou-
tine clinical practice. Each SMARTChip is single use
only. There will be no direct contact between patients
and the portable reader device, which itself does not
contain any biological or hazardous materials. The
risks from participation should be no greater than
standard clinical care, and there were no safety issues
reported in previous studies.
Study data collection will include documentation of
any complications following the blood-sampling proced-
ure or use of the SMARTChip reader device.
Should a medical event occur which is serious (results
in death, is life-threatening, requires inpatient hospital-
isation or prolongation of existing hospitalisation, results
in persistent or significant disability or incapacity, con-
sists of a congenital anomaly or birth defect, otherwise
considered significant by investigator) and is perceived
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to be related to the use of the SMARTChip assay, a sep-
arate study Serious Adverse Event form will be com-
pleted. All such events will be considered ‘unexpected’
and reported to the chief investigator, study sponsor and
Research Ethics Committee.
Sample size
1. Pilot study. There is no pre-specified sample size
for the hospital pilot study. This phase will continue
until agreement is reached about technical perform-
ance parameters as described below.
2. Hospital cohort study. In the hospital setting, we
consider that test specificity for mimics is more
important than sensitivity such that mimics are
directed away from the emergency stroke pathway
whilst minimising removal of stroke patients in
error. To detect a 90% (lower 95% confidence limit,
80%) diagnostic specificity for mimic identification
assuming a mimic rate of 25% (i.e. 75% non-mimic
or true stroke patients), one-tailed 5% type I error
rate and 90% power, 167 participants (125 non-
mimics) are required for the ‘per-protocol’ analysis.
For validation of the hospital statistical model
(combined clinical data and SMARTChip assay
reading), 100 further non-mimics are needed, i.e.
a further 134 patients in total. This gives a sample
size of 301 (225 non-mimics). However, this
target anticipates a non-mimic rate of 75% in
the test population. If the mimic rate is higher,
additional patients will be required. Inflating for
20% for participants who cannot feature in the
‘per-protocol’ analysis (see definition below in
‘Main hospital and ambulance study analyses’)
gives an initial target sample size of 377 participants
(including 281 non-mimics).
3. Ambulance cohort study. In the pre-hospital set-
ting, we consider that test sensitivity for mimics
is more important than specificity to maximise
removal of mimics from the emergency stroke
pathway for service efficiency. To detect an 88%
(lower 95% confidence limit, 80%) diagnostic sen-
sitivity for mimic identification assuming a mimic
rate of 40%, one-tailed 5% type I error rate and
90% power, 498 study participants (199 mimics)
are required for the ‘per-protocol’ analysis
(Agresti-Coull method [25]). For validation of the
statistical model (combined pre-clinical data and
SMARTChip assay reading), 100 further mimics
are needed [26], i.e. a further 250 patients in
total. This gives a sample size of 748 (299
mimics). However, this target reflects a typical
FAST mimic rate of 40% amongst suspected
stroke admissions. If the mimic rate is lower,
additional patients will be required. Inflating for
20% of participants who cannot feature in the
‘per-protocol’ analysis (see definition below in
‘Main hospital and ambulance study analyses’)
gives an initial target sample size of 935 patients
(including 374 mimics).
In both the hospital and ambulance cohorts, the pro-
portion of patients who are not eligible for inclusion in
the per-protocol analysis will be monitored prospect-
ively, and the sample size targets increased or decreased
as required.
Pilot study analysis
The technology supporting the SMARTChip WBPC
assay has undergone modification for use in this study.
Prior to embarking on a diagnostic performance evalu-
ation, it is necessary to confirm that key technical as-
pects are functioning as expected.
The following will be monitored although this is not
an exhaustive list and other issues may arise that will re-
quire review:
 Chip calibration failure rate
 Blood measurement failure rate
 Reader software malfunction
 The range of WBPC readings being obtained is
consistent with an expected range for suspected
stroke from previous studies. The range will be
monitored without access to clinical data.
This pilot phase will not be time or sample size
limited but driven by accruing data which will deter-
mine whether any action needs to be taken. The tech-
nology and/or user training may need to be revised in
an iterative way necessitating pause in patient testing
whilst this is achieved. If any technology change
would result in a change to the patient experience,
the protocol and/or patient facing information will be
amended accordingly and submitted for reapproval
prior to resuming testing.
To facilitate any investigations, it may be necessary to
share some clinical data collected (e.g. unblinded refer-
ence standard data) with Sarissa Biomedical and/or
study investigators. Only non-identifiable information
will be included.
The pilot phase will be considered completed and the
study to have entered phase 2 (main hospital cohort part
1) once Sarissa Biomedical and the study investigator
team are satisfied that accruing data indicates that the
technology is functioning as expected. Data collected in
the pilot phase which results in a pause to testing and al-
terations to the technology and/or training will not be
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used in any diagnostic performance evaluations (i.e.
phase 2 onwards).
A record will be kept of all alterations made to the
technology during the pilot phase.
Main hospital and ambulance study analyses
All statistical analysis will follow quality assurance pro-
cesses including taking account of relevant reporting
guidelines such as STARD (Standards for the Reporting
of Diagnostic Accuracy Studies) 2015 [27].
Visual data exploration
The data (i.e. WBPC measurements and clinical data)
will be explored with visualization tools such as histo-
grams, box and whisker plots and scattergrams to assess
distribution patterns, detect missing data and outliers
and look for associations and interactions between
variables.
Analytical data exploration
Data will be explored with analytic tools. Univariate ana-
lysis will be used to investigate the linearity of the rela-
tionships between the dependent and independent
variable(s). If relationship(s) are not linear, the log trans-
formation and squared transformation will be attempted.
If a transformation significantly lowers the Akaike Infor-
mation Criterion (AIC), then, the variable will be trans-
formed for use in the model selection step.
Analysis populations
There will be two analysis populations:
a) A per-protocol (PP) group will only include par-
ticipants who have a verified WBPC reading, a
reference standard diagnosis (i.e. not ‘unclear’)
and who met the inclusion and exclusion criteria.
In the emergency pre-hospital or hospital setting,
it is not uncommon for initial assessment infor-
mation to be later considered inaccurate as fur-
ther details emerge. Study data recorded about
eligibility information will be reviewed, and any
tested patients who did not meet the eligibility
criteria will not be included in the PP analysis.
In addition, for ambulance-tested patients, data
separately recorded at the hospital will be consid-
ered more accurate for age, symptom onset time
and receipt of chemotherapy or radiology, and
these data will be used instead of the ambulance-
recorded data to determine eligibility for the PP
group for these criteria.
b) An intention-to-test (ITT) group will include par-
ticipants who did and did not meet the eligibility
criteria and who had either a verified or an
unverified WBPC, and a reference standard diagno-
sis (‘unclear’ will not be included).
Data not contributing to analysis populations
For participants where it is not possible to assign a refer-
ence standard diagnosis (i.e. unclear), available data will
be reported but will not contribute to diagnostic accur-
acy analyses.
Where the WBPC assay technology fails prior to the
point of fingerprick sampling (i.e. calibration or buffer
failure), only limited data about the test will be recorded.
These data will be reported.
Statistical analyses
1. Objective 1: to determine the diagnostic accuracy of
SMARTChip assay WBPC readings for
identification of stroke mimic conditions when a
reading is obtained in the pre-hospital setting, i.e.
the test is conducted on patients suspected to have
stroke by ambulance staff
For the PP group, logistic regression analyses with bin-
ary diagnosis of mimic or stroke (with TIA grouped with
stroke as the intended purpose of the test is to identify
mimic) as the outcome variable and WBPC reading as
the explanatory variable will be used to construct a re-
ceiver operating curve (ROC) for all possible test thresh-
olds. Area under the ROC curve and optimal sensitivity,
specificity, and negative and positive predictive values, will
be reported with 95% confidence intervals (CI). Optimal
thresholds for sensitivity and specificity will be chosen. As
we consider that test sensitivity is more important than
specificity in the ambulance, the optimal threshold will be
chosen to maximise sensitivity for mimics, minimum 80%,
but aiming to keep estimated specificity for mimics above
70%. At lower levels of sensitivity and specificity, the test
is unlikely to be considered of value.
For the ITT group, sensitivity and specificity will be
calculated using a two-by-two table. Patients with a veri-
fied WBPC reading will be assigned a ‘test diagnosis’ ac-
cording to the optimal threshold established in the PP
analysis, and patients with an unverified WBPC will be
assigned a test diagnosis of stroke. If the SMARTChip
was deployed in clinical practice and an unverified read-
ing was obtained, patients would continue to be man-
aged as suspected stroke as there would be no extra
information to exclude this possibility.
2. Objective 2: to determine the diagnostic accuracy of
SMARTChip assay WBPC readings for
identification of stroke mimic conditions when a
reading is obtained in hospital, i.e. the test is
conducted on patients suspected to have stroke by
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hospital staff and when an ambulance test has not
been undertaken
For this objective, analyses as described above for ob-
jective 1 will be conducted. In terms of optimal thresholds,
as we consider that test specificity is more important than
sensitivity in hospital, the optimal threshold will be chosen
to maximise specificity for mimics, minimum 80%, but
aiming to keep estimated sensitivity for mimics above
70%. At lower levels of specificity and sensitivity, the test
is unlikely to be considered of value.
3. Objective 3: to develop pre-hospital and hospital
statistical models which combine routinely available
clinical data with SMARTChip assay WBPC read-
ings to predict a stroke mimic diagnosis
Key variables will be added to the PP models described
above to determine if this could significantly increase
their accuracy. Clinical variables that would be available
to ambulance/hospital staff will be included to reflect
those available at the point of testing. Stepwise regres-
sion with backward elimination will be used to select the
clinical covariates that most influence the diagnosis of
mimics in conjunction with the WBPC readings.
A stepwise variable selection procedure will be used,
and only variables that significantly improve the AIC will
be retained in the model. Sensitivity, specificity, ROC
AUC (with confidence intervals) and threshold will be
reported if a suitable model is found.
4. Objective 4: to prospectively determine the
diagnostic accuracy of the statistical models from
objective 3
The models derived under objective 3 will be used to
predict mimic/stroke status, and sensitivity, specificity
and negative and positive predictive values will be re-
ported with 95% confidence intervals (CI) for the PP
population.
5. Objective 5: to report the failure rate of the
SMARTChip assay when used in the pre-hospital
and hospital settings
Reasons why a SMARTChip assay measurement was
attempted but not obtained will be categorised and re-
ported. This will include the following:
– Failed SMARTChip calibration or buffer
– Failed SMARTChip reading following successful
calibration (i.e. unverified reading)
– User-reported clinical or operational reason for
aborting the calibration or reading process
A failure rate will be calculated for pre-hospital and
hospital settings.
6. Subgroup and exploratory analyses
Diagnosis accuracy calculations will be performed on a
pre-specified subgroup of the PP population consisting
of only those patients with a reference standard diagno-
sis of ‘Definite Stroke’ and ‘Definite Mimic’ (this sub-
group analysis is being undertaken as it considers the
highest level of clinical confidence in the diagnosis and
therefore allows exploration of the SMARTChip assay
performance under ideal conditions). Contingent on the
results of the study, it may be important to carry out
some data-driven exploratory analyses. These will be de-
termined post hoc and reported as such.
7. Substudy analysis
a) Sub-study objective 1: to explore the diagnostic
accuracy of two sequential SMARTChip assay
WBPC readings for identification of large vessel
occlusion stroke using a reading obtained in the
pre-hospital setting and a second reading ob-
tained in the hospital setting
This analysis will include only patients who have both
a pre-hospital- and hospital-verified WBPC reading, a
reference standard assigned and who meet all the eligi-
bility criteria for both tests.
Logistic regression analyses with diagnosis (LVO) as
the outcome, hospital WBPC reading as the explanatory
variable and pre-hospital WBPC reading as a covariate
will be used to construct a receiver operating curve
(ROC) for all possible test thresholds. Area under the
ROC curve and optimal sensitivity, specificity, and nega-
tive and positive predictive values will be reported with
95% confidence intervals (CI). As for the main in-
hospital study, the optimal threshold will be chosen to
maximise specificity.
b) Sub-study objective 2: to develop and
retrospectively explore the diagnostic accuracy of a
statistical model which combines routinely available
clinical data with pre-hospital- and hospital-
obtained SMARTChip WBPC readings to predict
the presence of large vessel occlusion.
Key variables will be added to the model described
above to determine if this could significantly increase its
accuracy. Clinical variables that would be available to
ambulance and/or hospital staff will be included to re-
flect those available at the point of testing. Multivariate
logistic regression will be conducted, with diagnosis
(LVO) as the outcome and pre-hospital and hospital
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WBPC readings along with variables considered to be of
possible clinical importance (such as blood pressure,
pre-hospital FAST symptoms, NIHSS) as the explanatory
variables. A stepwise variable selection procedure will be
used, and only variables that significantly improve the
ROC AUC will be retained in the model. Sensitivity, spe-
cificity, ROC AUC (with confidence intervals) and
threshold will be reported if a suitable model is found.
As for the main in-hospital study, the optimal threshold
will be chosen to maximise specificity.
c) Substudy subgroup and exploratory analyses
Contingent on the results of the study, it may be im-
portant to carry out some data-driven subgroup or ex-
ploratory analysis. These will be determined post hoc
and reported as such.
Study monitoring, quality control and quality assurance
The chief investigator will have overall responsibility for
study conduct. The local principal investigators will be
responsible for the day-to-day study conduct at their in-
dividual NHS sites. The study will be managed by a co-
ordinating centre based at Newcastle University who will
provide training and day-to-day support for the sites.
Quality control will be maintained through adherence to
the Newcastle Biomedicine Clinical Research Platform
standard operating procedures, the study protocol and
research governance regulations. The study may be sub-
ject to inspection and audit by the Northumbria Health-
care NHS Foundation Trust under their remit as
sponsor. A Study Steering Committee will be convened
to provide oversight of the trial. This will comprise of
the study investigators plus an independent member.
This committee will aim to meet 6 monthly.
Dissemination of results
The study will be presented at national and international
conferences and reported in peer-reviewed journals. Re-
ports will be written for the study funder, sponsor and
regulatory bodies. A lay summary of the results will be
available for study participants.
Discussion
Early diagnostic uncertainty about the cause of sus-
pected stroke symptoms results in displacement of non-
stroke mimic patients from more appropriate services,
inappropriate demands on specialist resources and de-
layed access to specialist care and time-critical reperfu-
sion therapies for stroke patients. Blood biomarkers have
not previously been shown to be useful in emergency
stroke assessment due to delayed elevation and a need
for complex assays [13–15]. In addition, markers of in-
flammatory response or vascular risk have not improved
upon clinical assessment alone [13, 28]. However, there
is now evidence to suggest that blood purine concentra-
tion which rises rapidly during hypoxic tissue injury may
be able to assist with urgent differentiation of stroke
from mimic conditions [16–19].
This study will determine the performance of a port-
able point of care fingerprick measurement of blood
purine concentration for the identification mimic pa-
tients within the suspected stroke population. We will
also consider whether blood purine readings show
greater diagnostic accuracy when combined with other
information available to clinicians such as symptom se-
verity. A substudy will explore whether serial purine
readings could be an early indicator of large vessel oc-
clusion which could be an alternative use of the test.
If test performance to identify non-stroke mimic con-
ditions is satisfactory, future deployment in ambulances
and emergency departments could assist with urgent tri-
age of patients with suspected stroke symptoms and en-
able more appropriate direction of patients to stroke or
non-stroke services. Improved service access could con-
sequently result in better outcomes through faster access
to appropriate treatments.
Study status
At the time of submission of this manuscript, recruit-
ment to the hospital cohort is in progress. Protocol ver-
sion 4 dated 14 July 2020 was used to prepare this
manuscript.
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